Evaluating 68Ga-FAPI PETCT Imaging for Diagnosing Various Malignant Tumors

What this Trial Is About

Researchers are investigating the diagnostic potential of a new molecular imaging probe called gallium 68-labelled fibroblast-activation protein inhibitor 68Ga-FAPI in detecting various malignant tumors. Fibroblast-activation protein FAP is commonly found in cancer-associated fibroblasts within tumor tissue and plays a role in tumor growth and spread. This study aims to confirm the advantages of 68Ga-FAPI over traditional imaging methods like 18F-fluorodeoxyglucose 18F-FDG PETCT, which can sometimes give false positive or negative results in certain cancers. Participants who have undergone whole-body 18F-FDG PETCT scans for suspected or confirmed malignancies, particularly tumors with low FDG uptake such as glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases, will receive a whole-body 68Ga-FAPI PETCT scan within one to four weeks. The 68Ga-FAPI is injected intravenously with a dose based on body weight, and imaging is performed 20 to 60 minutes after injection. This interventional study evaluates how well 68Ga-FAPI PETCT can diagnose and stage malignant tumors. During the study, participants will undergo the 68Ga-FAPI PETCT scan and be monitored for diagnostic sensitivity and specificity over three years. Researchers will also assess the prognostic value of FAPI PET parameters up to one year post-treatment, evaluate therapeutic response within one week after completion of therapy, and explore correlations between PET imaging and histopathological biomarkers within four weeks of the scan. The study includes informed consent and follow-up assessments to understand the imaging methods overall effectiveness in managing cancer.

68Ga-FAPI PET/CT in Malignant Tumors